TFDP3

Across TCGA pan-cancer cohorts, TFDP3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TFDP3 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TFDP3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TFDP3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, KIRC, and SKCM are the cancer types where TFDP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.387	0.209	.011	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TFDP3–ACC (DFS)

Open the ACC breakdown →